We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
+44.85%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$19.3M
AUM Growth
+$1.72M
(+9.8%)
Cap. Flow
+$309
Cap. Flow
% of AUM
0%
Top 10 Holdings %
Top 10 Hldgs %
48.51%
Holding
42
New
15
Increased
6
Reduced
10
Closed
3
Top Buys
| 1 |
Cue Biopharma
CUE
|
+$1.35M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$601K |
| 3 |
Humacyte
HUMA
|
+$590K |
| 4 |
uniQure
QURE
|
+$567K |
| 5 |
Janux Therapeutics
JANX
|
+$447K |
Top Sells
| 1 |
Mineralys Therapeutics
MLYS
|
+$1.14M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$912K |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
+$909K |
| 4 |
Insmed
INSM
|
+$900K |
| 5 |
Arcutis Biotherapeutics
ARQT
|
+$769K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Milestone Pharmaceuticals
MIST
$154M
| $1.53M | 7.89% |
755,000
+96,447
| +15% | +$208K |
|
2
Praxis Precision Medicines
PRAX
$8.59B
| $1.31M | 6.79% |
4,450
-1,250
| -22% | -$233K |
|
3
MoonLake Immunotherapeutics
MLTX
$1.59B
| $890K | 4.6% |
67,500
| – | – |
|
4
Fennec Pharmaceuticals
FENC
$363M
| $866K | 4.48% |
112,434
-10,566
| -9% | -$86.7K |
|
5
Jasper Therapeutics
JSPR
$21.7M
| $851K | 4.4% |
465,000
+66,442
| +17% | +$133K |
|
6
Benitec Biopharma
BNTC
$435M
| $835K | 4.32% |
62,000
| – | – |
|
7
Royalty Pharma
RPRX
$25.9B
| $827K | 4.28% |
21,400
| – | – |
|
8
Geron
GERN
$911M
| $763K | 3.95% |
578,000
+78,000
| +16% | +$97.9K |
|
9
Syndax Pharmaceuticals
SNDX
$2.01B
| $756K | 3.91% |
36,000
-19,000
| -35% | -$331K |
|
10
Ardelyx
ARDX
$1.27B
| $750K | 3.88% |
128,650
-34,100
| -21% | -$190K |
|
|
11
Cue Biopharma
CUE
$117M
| $673K | 3.48% |
+73,428
| New | +$1.35M |
|
12
Disc Medicine
IRON
$2.81B
| $643K | 3.33% |
8,100
-2,500
| -24% | -$211K |
|
|
13
Sarepta Therapeutics
SRPT
$1.82B
| $613K | 3.17% |
+28,500
| New | +$601K |
|
14
Biohaven
BHVN
$2.13B
| $584K | 3.02% |
51,700
+29,000
| +128% | +$359K |
|
|
15
Humacyte
HUMA
$178M
| $480K | 2.49% |
500,000
+416,500
| +499% | +$590K |
|
16
Kura Oncology
KURA
$967M
| $478K | 2.47% |
46,000
| – | – |
|
17
Seres Therapeutics
MCRB
$50.2M
| $470K | 2.43% |
31,570
+4,432
| +16% | +$77.3K |
|
|
CMPS
18
Compass Pathways
CMPS
$1.68B
| $400K | 2.07% |
58,000
| – | – |
|
|
DAWN
19
DELISTED
Day One Biopharmaceuticals
DAWN
| $391K | 2.03% |
42,000
| – | – |
|
20
Regenxbio
RGNX
$579M
| $383K | 1.98% |
26,600
-31,150
| -54% | -$388K |
|
21
BridgeBio Pharma
BBIO
$15.7B
| $382K | 1.98% |
5,000
-8,300
| -62% | -$545K |
|
|
22
Mineralys Therapeutics
MLYS
$2.39B
| $381K | 1.97% |
10,500
-28,500
| -73% | -$1.14M |
|
|
VTYX
23
DELISTED
Ventyx Biosciences
VTYX
| $375K | 1.94% |
+41,500
| New | +$310K |
|
24
Lantheus
LNTH
$6.84B
| $366K | 1.89% |
+5,500
| New | +$320K |
|
25
Dyne Therapeutics
DYN
$3.76B
| $352K | 1.82% |
+18,000
| New | +$341K |
|
Similar funds
PA
PA
SR
SCTC
SRA
CP
B
CVV